Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
During the quarter, we increased our positions in Nektar Therapeutics (NKTR), Abivax SA (ABVX), The Oncology Institute (TOI), and Evolv Technologies (EVLV). NKTR and ABVX...
— Paul Cerro
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Nektar Therapeutics
More institutional theses from Cedar Grove Capital Management
OneSpaWorld ($OSW) is an outsourced, asset-light provider of health, wellness, and spa services operating aboard international cruise ships and destination resorts. The manager re-entered...
Nektar Therapeutics ($NKTR) is a clinical biopharmaceutical firm developing rezpegaldesleukin (rezpeg) for autoimmune conditions, primarily atopic dermatitis and alopecia areata. The manager remains...
Hims & Hers Health ($HIMS) provides direct-to-consumer digital telehealth services, offering subscription consultations and personalized treatments across dermatology, sexual health, mental wellness, and weight loss. The manager is...